Recent estimates have
projected a total of over 40 country introductions of rotavirus vaccine by 2015; this figure is in addition to the five countries that introduced vaccine prior to 2012  and . Thus, for this analysis we have assumed that a total of 47 countries will adopt by 2015, based on current GAVI predictions. We estimated that 17 of the remaining buy Forskolin 25 countries would introduce vaccine by 2020, and 8 countries after 2020. See Table 2 for the complete list of countries. Some countries may graduate from GAVI eligibility before or after they have introduced vaccine. However, estimates of benefits and costs over the entire analysis timeframe account for all expected rounds of vaccination in currently eligible countries assuming that graduating countries will be able to adopt and/or sustain their rotavirus immunization programs after graduation. Vaccine prices were estimated from current and expected price agreements between the purchasing agents for GAVI-eligible countries (UNICEF and PAHO), and the vaccine manufacturers. The average price of rotavirus vaccine is expected to decline over the analysis timeframe. In 2011,
we used an initial vaccine price of $7.50 per dose for a 2-dose regimen based on existing multinational supplier contracts with low to middle-income countries and their agents, in Latin America . Between 2012 and 2015 we used an estimated average price of $3.50 per dose for a 2-dose regimen, based on pledges made Dabrafenib chemical structure by existing multinational suppliers . Beginning in 2016, the price falls to $2.00 and then to $1.50 in 2018, reflecting competition and price decline due to the projected entry of products from developing country manufacturers . We estimated vaccine
coverage using UNICEF/WHO best estimates for DPT1 and DTP2 for each country. Then, updated the estimates on the timing of routine vaccinations from Clark et al. were incorporated . We also assumed that the coverage rate for children at the highest risk of rotavirus mortality was 90% of the vaccination rate for other children, since children who die of diarrhea may have had less access to vaccination and other health care resources . One-way sensitivity analysis was conducted to assess the impact of specific variables on the number of deaths averted and cost-effectiveness of vaccination. Variables included rotavirus mortality incidence, vaccine efficacy, relative coverage (the adjustment made for inequitable vaccine access in those children most likely to die), vaccination program costs, and timing of vaccine dosing. A probabilistic uncertainty analysis was done to assess the combined effect of multiple variables on vaccination impact (deaths averted) and cost-effectiveness ($/DALY averted) in the base-case analysis.